As previously reported, BofA downgraded Prothena (PRTA) to Underperform from Neutral with a price target of $4, down from $22, after lead drug birtamimab failed its Phase 3 trial to treat Mayo Stage IV AL Amyloidosis. Prothena continues to develop PRX012, a monoclonal antibody for Alzheimer’s disease, but it is still in early development and the firm assumes a conservative stance on this opportunity as currently approved therapies have not met expectations, the analyst tells investors.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
- Make smarter investment decisions with TipRanks' Smart Investor Picks, delivered to your inbox every week.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on PRTA:
- Prothena downgraded to Underperform from Neutral at BofA
- AMD, Block upgraded: Wall Street’s top analyst calls
- Prothena downgraded to Neutral from Overweight at Cantor Fitzgerald
- Prothena’s Hold Rating: Clinical Trial Challenges and Financial Pressures
- Prothena price target lowered to $81 from $110 at Piper Sandler